TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Wiser Choices In Osteoporosis Choice II
Brief Summary: Emphasis in treating osteoporosis has been on T-scores rather than overall fracture risk. Fracture Risk Assessment Tool (FRAX) supports a risk sensitive approach to osteoporosis treatment by providing an absolute fracture risk. FRAX combined with a decision aid may promote a shared decision making approach with patients, allowing the clinician and patient to weigh potential fracture risk (without treatment), versus risk reduction with medication (including side effects and costs). OSTEOPOROSIS CHOICE II will test the effectiveness of:

* FRAX
* FRAX + decision aid
* Usual care (no decision aid and no FRAX given to clinician)


Options:
A: Arm Label: FRAX + Decision Aid; Type: EXPERIMENTAL; Interventions: Behavioral: FRAX + Decision Aid | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: FRAX estimated fracture risk; Type: EXPERIMENTAL; Interventions: Behavioral: FRAX estimated fracture risk | Intervention Type: BEHAVIORAL; Name: FRAX + Decision Aid; Assigned to Arm(s): FRAX + Decision Aid | Intervention Type: BEHAVIORAL; Name: FRAX estimated fracture risk; Assigned to Arm(s): FRAX estimated fracture risk
B: Arm Label: Diabetes Medication Choice decision aid; Type: EXPERIMENTAL; Interventions: Behavioral: Diabetes Medication Choice decision aid | Arm Label: Usual Care; Type: OTHER; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: Diabetes Medication Choice decision aid; Assigned to Arm(s): Diabetes Medication Choice decision aid | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual Care
C: Arm Label: Decision support; Type: EXPERIMENTAL; Interventions: Other: Feeding Options in Dementia Decision Aid | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Feeding Options in Dementia Decision Aid; Assigned to Arm(s): Decision support
D: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: MyHealthyChoices | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Other: Health Risk Assessment | Intervention Type: BEHAVIORAL; Name: MyHealthyChoices; Assigned to Arm(s): Intervention Group | Intervention Type: OTHER; Name: Health Risk Assessment; Assigned to Arm(s): Control Group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Site-Randomized Controlled Trial for Health Promotion in Girl Scouts: Healthier Troops in a SNAP
Brief Summary: The purpose of the study was to evaluate the effectiveness of an intervention designed to prevent obesity by improving the environmental characteristics of Girl Scouts troop meetings.


Options:
A: Intervention Type: BEHAVIORAL; Name: diet, reducing; Assigned to Arm(s): N/A
B: Arm Label: reducing beverages and sugar and increase physical activity; Type: EXPERIMENTAL; Interventions: Behavioral: lifestyle | Arm Label: control -no intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: lifestyle; Assigned to Arm(s): reducing beverages and sugar and increase physical activity
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Primary (Environmental) Weight Gain Prevention | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Behavioral: Primary (Environmental) Weight Gain Prevention, Behavioral: Secondary (Behavioral) Weight Gain Prevention | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Behavioral: Control | Intervention Type: BEHAVIORAL; Name: Primary (Environmental) Weight Gain Prevention; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: BEHAVIORAL; Name: Secondary (Behavioral) Weight Gain Prevention; Assigned to Arm(s): Arm 2 | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Arm 3
D: Arm Label: Scouting curricular implementation; Type: EXPERIMENTAL; Interventions: Behavioral: Scouting Nutrition and Activity Program | Arm Label: Standard-care attentional control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard-care attentional control | Intervention Type: BEHAVIORAL; Name: Scouting Nutrition and Activity Program; Assigned to Arm(s): Scouting curricular implementation | Intervention Type: BEHAVIORAL; Name: Standard-care attentional control; Assigned to Arm(s): Standard-care attentional control

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Site-Randomized Controlled Trial for Health Promotion in Girl Scouts: Healthier Troops in a SNAP
Brief Summary: The purpose of the study was to evaluate the effectiveness of an intervention designed to prevent obesity by improving the environmental characteristics of Girl Scouts troop meetings.


Options:
A: Arm Label: CHL program; Type: EXPERIMENTAL; Interventions: Other: CHL program | Arm Label: Delayed Optimized CHL program; Type: OTHER; Interventions: Other: Delayed Optimized CHL program | Arm Label: Temporal; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: CHL program; Assigned to Arm(s): CHL program | Intervention Type: OTHER; Name: Delayed Optimized CHL program; Assigned to Arm(s): Delayed Optimized CHL program
B: Arm Label: The Health Lifestyles Interventions; Type: EXPERIMENTAL; Interventions: Behavioral: The Health Lifestyles Interventions | Arm Label: Receive no intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: The Health Lifestyles Interventions; Assigned to Arm(s): The Health Lifestyles Interventions
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: KAN-DO | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: KAN-DO | Intervention Type: BEHAVIORAL; Name: KAN-DO; Assigned to Arm(s): 1, 2
D: Arm Label: Scouting curricular implementation; Type: EXPERIMENTAL; Interventions: Behavioral: Scouting Nutrition and Activity Program | Arm Label: Standard-care attentional control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard-care attentional control | Intervention Type: BEHAVIORAL; Name: Scouting Nutrition and Activity Program; Assigned to Arm(s): Scouting curricular implementation | Intervention Type: BEHAVIORAL; Name: Standard-care attentional control; Assigned to Arm(s): Standard-care attentional control

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Open-label, Phase III Study of BIBW 2992 Versus Chemotherapy as First-line Treatment for Patients With Stage IIIB or IV Adenocarcinoma of the Lung Harbouring an EGFR Activating Mutation
Brief Summary: This randomised, open label phase III trial will be performed in patients with adenocarcinoma of the lung with tumours harbouring an Epidermal Growth Factor Receptor activating mutation. The objectives of the trial are to compare the efficacy of single agent BIBW 2992, Arm A, with Pemetrexed/Cisplatin chemotherapy, Arm B, as first line treatment for this group of patients.


Options:
A: Arm Label: Cetuximab plus chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: cetuximab + cisplatin + vinorelbine | Arm Label: Chemotherapy alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: cisplatin + vinorelbine | Intervention Type: DRUG; Name: cetuximab + cisplatin + vinorelbine; Assigned to Arm(s): Cetuximab plus chemotherapy | Intervention Type: DRUG; Name: cisplatin + vinorelbine; Assigned to Arm(s): Chemotherapy alone
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Platinum chemotherapy (cisplatin or carboplatin), Drug: erlotinib [Tarceva], Drug: gemcitabine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Platinum chemotherapy (cisplatin or carboplatin), Drug: gemcitabine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Platinum chemotherapy (cisplatin or carboplatin); Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: erlotinib [Tarceva]; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: gemcitabine; Assigned to Arm(s): 1, 2
C: Arm Label: BIBW 2992; Type: EXPERIMENTAL; Interventions: Drug: BIBW 2992 | Arm Label: Cisplatin/Pemetrexed; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pemetrexed, Drug: Cisplatin | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Cisplatin/Pemetrexed | Intervention Type: DRUG; Name: BIBW 2992; Assigned to Arm(s): BIBW 2992 | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Cisplatin/Pemetrexed
D: Arm Label: Erlotinib; Type: EXPERIMENTAL; Interventions: Drug: Erlotinib | Arm Label: Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chemotherapy | Intervention Type: DRUG; Name: Erlotinib; Assigned to Arm(s): Erlotinib | Intervention Type: DRUG; Name: Chemotherapy; Assigned to Arm(s): Chemotherapy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label Multicenter Study on the Efficacy of Continuous Oral Dosing of Vemurafenib on Tumour Response in Previously Treated Patients With Metastatic Melanoma
Brief Summary: This open-label single arm study will assess the efficacy, safety and tolerability of Vemurafenib in previously treated patients with metastatic melanoma. Patients will receive oral Vemurafenib \[RG7204; PLEXXIKON: PLX4032\] at a dose of 960 mg b.i.d. continuously until disease progression or withdrawal from study and will be assessed at regular intervals for tumour response and tolerability. Target sample size is \<100 patients.


Options:
A: Arm Label: Single Arm; Type: EXPERIMENTAL; Interventions: Drug: GSK2118436 | Intervention Type: DRUG; Name: GSK2118436; Assigned to Arm(s): Single Arm
B: Arm Label: Single arm; Type: EXPERIMENTAL; Interventions: Drug: vemurafenib | Intervention Type: DRUG; Name: vemurafenib; Assigned to Arm(s): Single arm
C: Arm Label: A1; Type: EXPERIMENTAL; Interventions: Drug: Dacarbazine, Drug: Fotemustine | Arm Label: A2; Type: EXPERIMENTAL; Interventions: Drug: Dacarbazine, Drug: Fotemustine, Drug: Interferon Alfa-2b | Arm Label: B1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dacarbazine | Arm Label: B2; Type: EXPERIMENTAL; Interventions: Drug: Dacarbazine, Drug: Interferon Alfa-2b | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): A1, A2, B1, B2 | Intervention Type: DRUG; Name: Fotemustine; Assigned to Arm(s): A1, A2 | Intervention Type: DRUG; Name: Interferon Alfa-2b; Assigned to Arm(s): A2, B2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: ipilimumab (MDX-010, BMS-734016) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Ipilimumab | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Ipilimumab | Intervention Type: DRUG; Name: ipilimumab (MDX-010, BMS-734016); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Ipilimumab; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Ipilimumab; Assigned to Arm(s): 3

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vitamin D and Genetics in Nutritional Rickets
Brief Summary: The purpose of this study is:

1. To compare the response of rickets to calcium with and without vitamin D.
2. To assess whether vitamin D increases calcium absorption in calcium deficiency rickets.
3. To compare the response of children with and without rickets to orally administered vitamin D3 and vitamin D2
4. To identify mutations that influence calcium and vitamin D metabolism among families of children with rickets in Nigeria and Bangladesh.
5. To assess the functional status of the 25-hydroxylase enzyme in families possessing a 25-hydroxylase mutation.


Options:
A: Arm Label: Usual care group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: High Dose Group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Cholecalciferol | Intervention Type: DIETARY_SUPPLEMENT; Name: Cholecalciferol; Assigned to Arm(s): High Dose Group
B: Arm Label: Vitamin D (10 microgram/day); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 (cholecalciferol) | Arm Label: Vitamin D (20 microgram/day); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 (cholecalciferol) | Arm Label: Placebo control; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3 (cholecalciferol); Assigned to Arm(s): Vitamin D (10 microgram/day), Vitamin D (20 microgram/day)
C: Arm Label: Vitamin D + Calcium; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D + Calcium | Arm Label: Calcium; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Calcium | Arm Label: Vitamin D2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D2 | Arm Label: Vitamin D3; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D + Calcium; Assigned to Arm(s): Vitamin D + Calcium | Intervention Type: DIETARY_SUPPLEMENT; Name: Calcium; Assigned to Arm(s): Calcium | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D2; Assigned to Arm(s): Vitamin D2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Vitamin D3
D: Arm Label: Multivitamins; Type: EXPERIMENTAL; Interventions: Drug: Multivitamins - vitamins B complex, C and E | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Multivitamins - vitamins B complex, C and E; Assigned to Arm(s): Multivitamins | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-week, Randomised, Double-blind, Placebo-controlled, Parallel Group, Multinational, Phase IIb Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at 3 Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium
Brief Summary: The primary objective is to evaluate the dose-response relationship and efficacy of AZD9668 at 3 dose levels compared with placebo in symptomatic COPD patients by assessing effects on lung function and symptoms of COPD.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: AZD9668 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: AZD9668 | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: AZD9668 | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: AZD9668 Placebo | Intervention Type: DRUG; Name: AZD9668; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: AZD9668; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: AZD9668; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: AZD9668 Placebo; Assigned to Arm(s): 4
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: MP-376 240 mg Twice Daily (BID); Type: EXPERIMENTAL; Interventions: Drug: MP-376 | Intervention Type: DRUG; Name: MP-376; Assigned to Arm(s): MP-376 240 mg Twice Daily (BID) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: COPD subjects; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Non-smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Intervention Type: OTHER; Name: Novel endpoint determination; Assigned to Arm(s): COPD subjects, Non-smoker controls, Smoker controls
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD9668 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AZD9668; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-week, Randomised, Double-blind, Placebo-controlled, Parallel Group, Multinational, Phase IIb Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at 3 Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium
Brief Summary: The primary objective is to evaluate the dose-response relationship and efficacy of AZD9668 at 3 dose levels compared with placebo in symptomatic COPD patients by assessing effects on lung function and symptoms of COPD.


Options:
A: Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: AZD9668 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: AZD9668 | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: AZD9668 | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: AZD9668 Placebo | Intervention Type: DRUG; Name: AZD9668; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: AZD9668; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: AZD9668; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: AZD9668 Placebo; Assigned to Arm(s): 4
C: Arm Label: Indacaterol 150 µg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 150 µg, Drug: Placebo to salmeterol | Arm Label: Salmeterol 50 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol 50 µg, Drug: Placebo to indacaterol | Intervention Type: DRUG; Name: Indacaterol 150 µg; Assigned to Arm(s): Indacaterol 150 µg | Intervention Type: DRUG; Name: Salmeterol 50 µg; Assigned to Arm(s): Salmeterol 50 µg | Intervention Type: DRUG; Name: Placebo to indacaterol; Assigned to Arm(s): Salmeterol 50 µg | Intervention Type: DRUG; Name: Placebo to salmeterol; Assigned to Arm(s): Indacaterol 150 µg
D: Arm Label: Relovair; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Novel Dry Powder Inhaler (NDPI) | Arm Label: Tiotropium; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium | Intervention Type: DRUG; Name: fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Novel Dry Powder Inhaler (NDPI); Assigned to Arm(s): Relovair | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Tiotropium

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Post-Surgical Stereotactic Radiosurgery for Metastatic Brain Disease: A Randomized Trial
Brief Summary: This randomized phase III trial studies stereotactic radiosurgery to see how well it works compared to clinical observation after surgery in treating patients with brain metastases. Stereotactic radiosurgery, a type of radiation therapy, may be able to send x-rays directly to the tumor and cause less damage to normal tissue.


Options:
A: Intervention Type: PROCEDURE; Name: adjuvant therapy; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: stereotactic radiosurgery; Assigned to Arm(s): N/A
B: Arm Label: Surgery + Whole Brain Radiotherapy; Type: OTHER; Interventions: Procedure: Surgery + WBRT | Arm Label: RadioSurgery + Whole Brain Radiotherapy; Type: EXPERIMENTAL; Interventions: Radiation: Radiosurgery + WBRT | Intervention Type: PROCEDURE; Name: Surgery + WBRT; Assigned to Arm(s): Surgery + Whole Brain Radiotherapy | Intervention Type: RADIATION; Name: Radiosurgery + WBRT; Assigned to Arm(s): RadioSurgery + Whole Brain Radiotherapy
C: Arm Label: Arm I - WBRT; Type: ACTIVE_COMPARATOR; Interventions: Radiation: whole-brain radiation therapy | Arm Label: Arm II - SRS; Type: EXPERIMENTAL; Interventions: Radiation: stereotactic radiosurgery | Intervention Type: RADIATION; Name: stereotactic radiosurgery; Assigned to Arm(s): Arm II - SRS | Intervention Type: RADIATION; Name: whole-brain radiation therapy; Assigned to Arm(s): Arm I - WBRT
D: Arm Label: Arm I (SRS); Type: EXPERIMENTAL; Interventions: Radiation: Stereotactic Radiosurgery | Arm Label: Arm II (observation); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: RADIATION; Name: Stereotactic Radiosurgery; Assigned to Arm(s): Arm I (SRS)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Randomized Double Blind Study Comparing the Effect of Oropharyngeal Decontamination by Povidone-iodine to Placebo on Ventilator-associated Pneumonia in Patients With Head Trauma or Cerebral Hemorrhage
Brief Summary: Head trauma and severe cerebral hemorrhage are major risk factors for development of ventilator-associated pneumonia. In a previous open labelled, single center study the investigators showed that repeated oropharyngeal decontamination with povidone-iodine may be an effective strategy to decrease the prevalence of ventilator-associated pneumonia in patients with head trauma. The present study aims to confirm these results in a multicenter, double blind study including patients suffering from head trauma or cerebral hemorrhage.


Options:
A: Arm Label: Placebo (Vehicle Control); Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 0.12% chlorhexidine gluconate oral rinse; Type: EXPERIMENTAL; Interventions: Drug: chlorhexidine gluconate oral rinse (0.12%) | Arm Label: 0.12% chlorhexidine oral rinse; Type: EXPERIMENTAL; Interventions: Drug: chlorhexidine gluconate oral rinse (0.12%), Drug: placebo | Intervention Type: DRUG; Name: chlorhexidine gluconate oral rinse (0.12%); Assigned to Arm(s): 0.12% chlorhexidine gluconate oral rinse, 0.12% chlorhexidine oral rinse | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 0.12% chlorhexidine oral rinse, Placebo (Vehicle Control)
B: Arm Label: povidone iodine; Type: EXPERIMENTAL; Interventions: Drug: povidone iodine | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: povidone iodine; Assigned to Arm(s): povidone iodine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
C: Arm Label: Toothbrushing with a manual brush; Type: EXPERIMENTAL; Interventions: Device: Toothbrushing with a manual brush | Arm Label: No toothbrushing; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Toothbrushing with a manual brush; Assigned to Arm(s): Toothbrushing with a manual brush
D: Arm Label: Biotene OralBalance® gel Arm; Type: EXPERIMENTAL; Interventions: Drug: Biotene OralBalance® gel | Arm Label: Sterile Water Arm; Type: PLACEBO_COMPARATOR; Interventions: Other: Sterile Water moisten cotton tipped applicator | Intervention Type: DRUG; Name: Biotene OralBalance® gel; Assigned to Arm(s): Biotene OralBalance® gel Arm | Intervention Type: OTHER; Name: Sterile Water moisten cotton tipped applicator; Assigned to Arm(s): Sterile Water Arm

Answer: B